க்ரேமேர்ச் நகர்ப்புற மருந்துகள் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article
Share this article
PHILADELPHIA, May 5, 2021 /PRNewswire/ Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2021 third quarter ended March 31, 2021. 
In recent months, we have significantly advanced a number of strategic initiatives, said Tim Crew, chief executive officer of Lannett. In April, we successfully completed a transaction to refinance our debt, using the proceeds to retire the outstanding Term Loan B balance of approximately $540 million that was set to mature in November of next year. As a result, we have extended the maturity of our debt to 2026 from 2022, which is after several high-value pipeline assets are expected to be commercialized. Moreover, we improved our free cash flow, by approximately $50 million in the first year alone, which we plan to use, in part, to support our growth initiatives. ....

United States , Robert Jaffe , Flovent Diskus , Lannett Company , Prnewswire Lannett Company Inc , Silarx Pharmaceuticals Inc , Kremers Urban Pharmaceuticals Inc , Exchange Commission , Recro Gainesville , Lannett Company Inc , Robert Jaffe Co , Tim Crew , Abbreviated New Drug Application , Call Information , Senior Convertible Note , Silarx Pharmaceuticals , Term Loan , Chief Financial Officer , Kremers Urban Pharmaceuticals , ஒன்றுபட்டது மாநிலங்களில் , ராபர்ட் ஜாஃப் , லானெட் நிறுவனம் , க்ரேமேர்ச் நகர்ப்புற மருந்துகள் இன்க் , பரிமாற்றம் தரகு , லானெட் நிறுவனம் இன்க் , ராபர்ட் ஜாஃப் இணை ,